■在接受经皮冠状动脉介入治疗(PCI)的患者中,短期双联抗血小板治疗(DAPT)后,P2Y12抑制剂单药治疗的疗效是否取决于P2Y12抑制剂的类型,目前尚不清楚.
■评估PCI术后替格瑞洛单药或氯吡格雷单药治疗与标准DAPT治疗的风险和益处。
■MEDLINE,Embase,TCTMD,和欧洲心脏病学会网站从开始到2023年9月10日被搜索,没有语言限制.
■纳入的研究是随机临床试验,比较P2Y12抑制剂单药治疗与DAPT对无口服抗凝治疗指征的PCI患者的判定终点。
■将每个试验提供的患者水平数据合成到合并数据集中,并使用1步混合效应模型进行分析。该研究是在个人参与者数据的系统评价和荟萃分析的首选报告项目之后报告的。
■主要目的是确定替格瑞洛或氯吡格雷单一疗法与DAPT对复合死亡的非劣效性,心肌梗死(MI),在符合方案分析中或卒中,风险比(HR)为1.15。关键次要终点是大出血和净不良临床事件(NACE)。包括主要终点和大出血。
■分析包括6项随机试验,包括25960名接受PCI的患者,其中24394名患者(12403名患者接受DAPT;8292名患者接受替格瑞洛单药治疗;3654名患者接受氯吡格雷单药治疗;45名患者接受普拉格雷单药治疗)保留在符合方案分析中。替格瑞洛单药治疗试验在亚洲进行,欧洲,和北美;氯吡格雷单一疗法的试验都在亚洲进行。在主要终点,替格瑞洛不劣于DAPT(HR,0.89;95%CI,0.74-1.06;非劣效性P=.004),但氯吡格雷并非不差(HR,1.37;95%CI,1.01-1.87;非劣效性P>.99),这一发现是由非心血管死亡驱动的。两种替格瑞洛的大出血风险较低(HR,0.47;95%CI,0.36-0.62;P<.001)和氯吡格雷单一疗法(HR,0.49;95%CI,0.30-0.81;P=.006;交互作用的P=0.88)。替格瑞洛的NACE降低(HR,0.74;95%CI,0.64-0.86,P<.001),但氯吡格雷单药治疗无效(HR,1.00;95%CI,0.78-1.28;P=.99;交互作用的P=.04)。
■这项系统评价和荟萃分析发现,替格瑞洛单药治疗全因死亡不劣于DAPT,MI,或中风和优于大出血和NACE。氯吡格雷单药治疗与出血减少类似,但在全因死亡方面并非不劣于DAPT,MI,或中风,很大程度上是因为在1项完全纳入东亚患者的试验中观察到的风险,以及由过度非心血管死亡引起的危险.
UNASSIGNED: Among patients undergoing percutaneous coronary intervention (PCI), it remains unclear whether the treatment efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy (DAPT) depends on the type of P2Y12 inhibitor.
UNASSIGNED: To assess the risks and benefits of
ticagrelor monotherapy or clopidogrel monotherapy compared with standard DAPT after PCI.
UNASSIGNED: MEDLINE, Embase, TCTMD, and the European Society of Cardiology website were searched from inception to September 10, 2023, without language restriction.
UNASSIGNED: Included studies were randomized clinical trials comparing P2Y12 inhibitor monotherapy with DAPT on adjudicated end points in patients without indication to oral anticoagulation undergoing PCI.
UNASSIGNED: Patient-level data provided by each trial were synthesized into a pooled dataset and analyzed using a 1-step mixed-effects model. The study is reported following the Preferred Reporting Items for Systematic
Review and Meta-Analyses of Individual Participant Data.
UNASSIGNED: The primary objective was to determine noninferiority of
ticagrelor or clopidogrel monotherapy vs DAPT on the composite of death, myocardial infarction (MI), or stroke in the per-protocol analysis with a 1.15 margin for the hazard ratio (HR). Key secondary end points were major bleeding and net adverse clinical events (NACE), including the primary end point and major bleeding.
UNASSIGNED: Analyses included 6 randomized trials including 25 960 patients undergoing PCI, of whom 24 394 patients (12 403 patients receiving DAPT; 8292 patients receiving ticagrelor monotherapy; 3654 patients receiving clopidogrel monotherapy; 45 patients receiving prasugrel monotherapy) were retained in the per-protocol analysis. Trials of ticagrelor monotherapy were conducted in Asia, Europe, and North America; trials of clopidogrel monotherapy were all conducted in Asia. Ticagrelor was noninferior to DAPT for the primary end point (HR, 0.89; 95% CI, 0.74-1.06; P for noninferiority = .004), but clopidogrel was not noninferior (HR, 1.37; 95% CI, 1.01-1.87; P for noninferiority > .99), with this finding driven by noncardiovascular death. The risk of major bleeding was lower with both
ticagrelor (HR, 0.47; 95% CI, 0.36-0.62; P < .001) and clopidogrel monotherapy (HR, 0.49; 95% CI, 0.30-0.81; P = .006; P for interaction = 0.88). NACE were lower with ticagrelor (HR, 0.74; 95% CI, 0.64-0.86, P < .001) but not with clopidogrel monotherapy (HR, 1.00; 95% CI, 0.78-1.28; P = .99; P for interaction = .04).
UNASSIGNED: This systematic
review and meta-analysis found that
ticagrelor monotherapy was noninferior to DAPT for all-cause death, MI, or stroke and superior for major bleeding and NACE. Clopidogrel monotherapy was similarly associated with reduced bleeding but was not noninferior to DAPT for all-cause death, MI, or stroke, largely because of risk observed in 1 trial that exclusively included East Asian patients and a hazard that was driven by an excess of noncardiovascular death.